Phase III Clinical Study of VC004 in Patients With Localized Advanced/ Metastatic Solid Tumors

Inclusion Criteria: * All subjects or legal representatives are willing and able to sign ICF approved by the ethics committee before starting any screening procedures； * Male or female, age ≥12 years old; Exclusion Criteria: * Patients have undergone major surgery within 4 weeks prior to the first dose or are expected to undergo major surgery during the trial (excluding vascular access establishment procedures, biopsy procedures); * Adverse reactions caused by previous treatment have not recovered to ≤1 grade (evaluated by the investigator); * Patients had been treated with a strong CYP3A inhibitor or inducer within 7 days prior to the first administration of the study drug.